GLYCIPHAGE®-S Tablets
Composition:
GLYCIPHAGE®-S
- Each uncoated bilayered tablet contains:
- Metformin Hydrochloride I.P. …... 500 mg (In sustained-release form)
- Sitagliptin ..............……………….………….….. 50 mg
- Excipients …………………………………......….… q.s.
- Colourn- Titanium Diaoxide I.P.
Description
- GLYCIPHAGE®-S tackles the increase in blood glucose levels not controlled by monotherapy along with providing once a day dosage convenience. GLYCIPHAGE®-S contains two oral anti-hyperglycaemic drugs, Metformin Sustained-release, Sitagliptin used in the management of Type 2 Diabetes.
- Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. Sitagliptin is a Dipeptidyl peptidase - 4 inhibitor, which indirectly increases insulin secretion and release by preventing degradation of incretins by inhibiting enzyme di-peptidyl peptidase-4.
- Hence, the combination of Metformin sustained-release and Sitagliptin complement each other and provide better glycaemic control in the management of Type 2 Diabetes and probably helps in the prevention of diabetes-associated macrovascular and microvascular complications.
Indications
- GLYCIPHAGE®-S is indicated as therapy when diet, exercise and monotherapy do not result in adequate glycaemic control in patients with type 2 diabetes.